• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    7/4/24 8:06:00 AM ET
    $ABSI
    $AMIX
    $AWH
    $CNSP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABSI alert in real time by email

    Gainers

    • CNS Pharma (NASDAQ:CNSP) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $2.2 million.
    • Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 37.23% to $1.29. The company's market cap stands at $24.3 million.
    • Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 21.37% to $1.59. The company's market cap stands at $1.5 million.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) stock increased by 13.63% to $2.5. The market value of their outstanding shares is at $1.4 million.
    • Absci (NASDAQ:ABSI) stock increased by 13.46% to $3.37. The company's market cap stands at $381.0 million.
    • Traws Pharma (NASDAQ:TRAW) stock increased by 12.32% to $0.41. The market value of their outstanding shares is at $10.3 million.

    Losers

    • Gain Therapeutics (NASDAQ:GANX) stock declined by 15.5% to $1.01 during Thursday's pre-market session. The market value of their outstanding shares is at $25.4 million.
    • Senti Biosciences (NASDAQ:SNTI) shares fell 11.11% to $0.35. The market value of their outstanding shares is at $15.8 million.
    • DIH Holding US (NASDAQ:DHAI) shares decreased by 9.1% to $2.5. The market value of their outstanding shares is at $101.3 million.
    • Trxade Health (NASDAQ:MEDS) shares declined by 8.82% to $16.86. The company's market cap stands at $23.7 million.
    • EUDA Health Holdings (NASDAQ:EUDA) shares decreased by 8.32% to $3.42. The market value of their outstanding shares is at $120.1 million.
    • Aspira Womens Health (NASDAQ:AWH) stock decreased by 7.77% to $0.95. The market value of their outstanding shares is at $11.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI
    $AMIX
    $AWH
    $CNSP

    CompanyDatePrice TargetRatingAnalyst
    Absci Corporation
    $ABSI
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    Traws Pharma Inc.
    $TRAW
    12/3/2025$8.00Buy
    H.C. Wainwright
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Absci Corporation
    $ABSI
    10/2/2025Overweight
    Analyst
    Absci Corporation
    $ABSI
    7/3/2025$7.00Overweight
    Morgan Stanley
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    Gain Therapeutics Inc.
    $GANX
    3/7/2025$12.00Sector Outperform
    Scotiabank
    Absci Corporation
    $ABSI
    1/22/2025$9.00Buy
    Needham
    More analyst ratings

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    H.C. Wainwright initiated coverage on Traws Pharma with a new price target

    H.C. Wainwright initiated coverage of Traws Pharma with a rating of Buy and set a new price target of $8.00

    12/3/25 7:50:46 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Senti Bio with a new price target

    H.C. Wainwright initiated coverage of Senti Bio with a rating of Buy and set a new price target of $12.00

    10/14/25 8:53:29 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    SEC Filings

    View All

    Traws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Traws Pharma, Inc. (0001130598) (Filer)

    2/19/26 8:42:35 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    2/17/26 8:35:58 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CNS Pharmaceuticals Inc.

    SCHEDULE 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    2/13/26 5:02:32 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Houten Frans bought $148,800 worth of shares (40,000 units at $3.72), increasing direct ownership by 172% to 63,320 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    12/9/25 4:04:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mcclain Sean exercised 396,399 shares at a strike of $1.21 and covered exercise/tax liability with 267,008 shares, increasing direct ownership by 2% to 8,463,958 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    2/25/26 6:05:16 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Innovation Officer Busch Andreas covered exercise/tax liability with 1,469 shares, decreasing direct ownership by 0.45% to 322,703 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    2/4/26 4:53:14 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Mcclain Sean sold $80,015 worth of shares (26,761 units at $2.99), decreasing direct ownership by 0.32% to 8,334,567 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    2/4/26 4:52:29 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation

    CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. As part of the segment, Mr. Hauser discusses Autonomix's publication strategy and the Company's focused efforts over the past 12 to 18 months to expand its scientific publication and presentation footprint. He emphasizes that submitting clinical and tec

    2/25/26 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

    Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs.

    11/13/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results

    NORWELL, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH" or the "Company") (NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. Recent Highlights Revenue of $62.9 million for the fiscal year ended March 31, 2025, representing a decrease of 2.5% over the prior year Device revenue of $49.7

    10/20/25 5:05:09 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

    NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws' Board of Directors (the "Board") has eliminated the interim notation of its key executives Iain Dukes and Charles Parker, who are now Chief Executive Officer and Chief Financial Officer, respectively. "Dr. Leaman brings more than a decade of experience in finance, M&A and

    10/6/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based a

    2/20/26 8:50:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABSI
    $AMIX
    $AWH
    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care